Analysts forecast that Integer Holdings Corp (NYSE:ITGR) will post sales of $312.95 million for the current quarter, according to Zacks. Two analysts have issued estimates for Integer’s earnings, with the lowest sales estimate coming in at $311.60 million and the highest estimate coming in at $314.30 million. Integer posted sales of $305.09 million in the same quarter last year, which suggests a positive year-over-year growth rate of 2.6%. The company is scheduled to report its next quarterly earnings results on Thursday, November 7th.
On average, analysts expect that Integer will report full-year sales of $1.27 billion for the current year. For the next fiscal year, analysts expect that the business will post sales of $1.33 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Integer.
Integer (NYSE:ITGR) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.17. The firm had revenue of $314.20 million during the quarter, compared to the consensus estimate of $318.50 million. Integer had a net margin of 15.73% and a return on equity of 13.31%. The company’s revenue was down .1% on a year-over-year basis. During the same quarter last year, the company earned $1.06 earnings per share.
Shares of ITGR traded down $2.74 during trading hours on Tuesday, hitting $73.45. The company’s stock had a trading volume of 4,134 shares, compared to its average volume of 168,014. The company has a market cap of $2.52 billion, a price-to-earnings ratio of 19.47 and a beta of 0.96. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.42 and a quick ratio of 1.41. The business has a 50 day simple moving average of $81.66 and a two-hundred day simple moving average of $79.17. Integer has a 52-week low of $67.72 and a 52-week high of $92.61.
In related news, Director Jean M. Hobby sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $80.19, for a total transaction of $481,140.00. Following the completion of the transaction, the director now owns 15,475 shares of the company’s stock, valued at $1,240,940.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 2.24% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of ITGR. BlackRock Inc. lifted its position in Integer by 2.8% during the second quarter. BlackRock Inc. now owns 4,892,982 shares of the medical equipment provider’s stock valued at $410,619,000 after purchasing an additional 133,532 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Integer by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 3,924,329 shares of the medical equipment provider’s stock worth $329,329,000 after acquiring an additional 114,503 shares during the last quarter. FMR LLC lifted its holdings in shares of Integer by 118.9% in the 1st quarter. FMR LLC now owns 950,210 shares of the medical equipment provider’s stock worth $71,664,000 after acquiring an additional 516,080 shares during the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in shares of Integer by 22.4% in the 2nd quarter. Silvercrest Asset Management Group LLC now owns 943,985 shares of the medical equipment provider’s stock worth $79,219,000 after acquiring an additional 172,758 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Integer by 6.3% in the 2nd quarter. Northern Trust Corp now owns 854,642 shares of the medical equipment provider’s stock worth $71,723,000 after acquiring an additional 51,001 shares during the last quarter. 97.51% of the stock is owned by institutional investors.
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
Featured Story: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.